Advanced search
Publication Cover
Cancer Investigation Volume 20, 2002 - Issue 2
Submit an article Journal homepage
20
Views
3
CrossRef citations to date
0
Altmetric
Original

A Phase II Trial of Interferon-Alpha and Toremifene in Advanced Renal Cell Cancer Patients

William K. Oh Lank Center for Genitourinary Oncology, Department of Adult Oncology, Dana-Farber Cancer Institute and Harvard Medical School, 44 Binney Street, Boston, MA, 02115, U.S.A.
, M.D.,
Judith Manola Lank Center for Genitourinary Oncology, Department of Adult Oncology, Dana-Farber Cancer Institute and Harvard Medical School, 44 Binney Street, Boston, MA, 02115, U.S.A.
, M.S.,
Daniel J. George Lank Center for Genitourinary Oncology, Department of Adult Oncology, Dana-Farber Cancer Institute and Harvard Medical School, 44 Binney Street, Boston, MA, 02115, U.S.A.
, M.D.,
Abby Fierman Lank Center for Genitourinary Oncology, Department of Adult Oncology, Dana-Farber Cancer Institute and Harvard Medical School, 44 Binney Street, Boston, MA, 02115, U.S.A.
,
Pamela Fontaine-Rothe Lank Center for Genitourinary Oncology, Department of Adult Oncology, Dana-Farber Cancer Institute and Harvard Medical School, 44 Binney Street, Boston, MA, 02115, U.S.A.
,
Stephanie Morrissey Lank Center for Genitourinary Oncology, Department of Adult Oncology, Dana-Farber Cancer Institute and Harvard Medical School, 44 Binney Street, Boston, MA, 02115, U.S.A.
,
Judith Prisby Lank Center for Genitourinary Oncology, Department of Adult Oncology, Dana-Farber Cancer Institute and Harvard Medical School, 44 Binney Street, Boston, MA, 02115, U.S.A.
,
Donald S. Kaufman Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, Massachusetts, U.S.A.
, M.D.,
Charles L. Shapiro Arthur James Cancer Center, Ohio State University, Columbus, Ohio, U.S.A.
, M.D.,
Philip W. Kantoff Lank Center for Genitourinary Oncology, Department of Adult Oncology, Dana-Farber Cancer Institute and Harvard Medical School, 44 Binney Street, Boston, MA, 02115, U.S.A.
, M.D. &
Matthew R. Smith Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, Massachusetts, U.S.A.
, M.D., Ph.D. show all
Pages 186-191 | Published online: 04 Sep 2002

REFERENCES

  • Motzer R.J., Russo P. Systemic Therapy for Renal Cell Carcinoma. J. Urol. 2000; 163(2)408–417
  • Yagoda A., Abi-Rached B., Petrylak D. Chemotherapy for Advanced Renal Cell Carcinoma. Semin. Oncol. 1995; 22: 42–60
  • Wirth M.P. Immunotherapy for Metastatic Renal Cell Carcinoma. Urol. Clin. North Am. 1993; 20: 283–295
  • Baron S., Tyring S.K., Fleischmann R., , et al. The Interferons: Mechanisms of Action and Clinical Application. JAMA 1991; 266: 1375–1383
  • Gelmann E.P. Tamoxifen for the Treatment of Malignancies Other than Breast and Endometrial Carcinoma. Semin. Oncol. 1997; 24(1 Suppl. 1)S1-65–S1-70
  • Glick J.H., Wein A., Torri S., , et al. Study of Tamoxifen in Patients with Advanced Renal Cell Carcinoma. Cancer Treat. Rep. 1980; 64(2–3)343–344
  • Al-Sarraf M., Eyre H., Bonnet J., , et al. Study of Tamoxifen in Metastatic Renal Cell Carcinoma and the Influence of Certain Prognostic Factors: A Southwest Oncology Group Study. Cancer Treat. Rep. 1981; 65(5–6)447–451
  • Weiselberg L., Budman D., Vinciguerra V., Degnan T.J. Tamoxifen in Unresectable Hypernephoma: A Phase II Trial and Review of the Literature. Cancer Clin. Trials. 1981; 4(2)195–198
  • Lanteri V.J., Dragone N., Choudhury M., , et al. High-dose Tamoxifen in Metastatic Renal Cell Carcinoma. Urology 1982; 19(6)623–625
  • Stahl M., Schmoll E., Becker H., , et al. Lonidamine vs. High-dose Tamoxifen in Progressive Advanced Renal Cell Carcinoma: Results of an Ongoing Randomized Phase II Study. Semin. Oncol. 1991; 182(Suppl. 4)33–37
  • Stahl M., Wilke H., Schmoll H.J., , et al. A Phase II Study of High Dose Tamoxifen in Progressive Metastatic Renal Cell Carcinoma. Ann. Oncol. 1992; 3(2)167–168
  • Papac R.J., Keohane M.F. Hormonal Therapy for Metastatic Renal Cell Carcinoma: Combined Androgen and Provera Followed by High Dose Tamoxifen. Eur. J. Cancer 1993; 29A(7)997–999
  • Schomburg A., Kirchner H., Fenner M., , et al. Lack of Therapeutic Efficacy of Tamoxifen in Advanced Renal Cell Carcinoma. Eur. J. Cancer 1993; 29A(5)737–740
  • Henriksson R., Nilsson S., Colleen S., , et al. Survival in Renal Cell Carcinoma—A Randomized Evaluation of Tamoxifen vs Interleukin 2, Alpha-Interferon (Leucocyte) and Tamoxifen. Br. J. Cancer 1998; 77(8)1311–1317
  • Hayes D.F., Van Zyl J.A., Hacking A., , et al. Randomized Comparison of Tamoxifen and Two Doses of Toremiphene in Postmenopausal Patients with Metastatic Breast Cancer. J. Clin. Oncol. 1995; 13: 2556–2566
  • Gershanovich M.M., Moiseyenko V.M., Vorobjev A.V., , et al. High-Dose Toremifene in Advanced Renal Cell Carcinoma. Cancer Chemother. Pharmacol. 1997; 39(6)547–551
  • Van den Berg H.W., Leahy W.J., Lynch M., , et al. Recombinant Human Interferon Alpha Increases Oestrogen Receptor Expression in Human Breast Cancer Cell Cells (Zr-75-1) and Sensitizes Them to the Anti-Proliferative Effects of Tamoxifen. Br. J. Cancer 1987; 55(3)255–257
  • Coradini D., Biffi A., Pirrolnello E., Di Fronzo G. Tamoxifen and Beta-Interferon: Effect of Simultaneous or Sequential Treatment on Breast Cancer Cell Lines. Anticancer Res. 1995; 15(2)315–319
  • Lindner D.J., Borden E.C. Synergistic Antitumor Effects of a Combination of Interferon and Tamoxifen on Estrogen Receptor-Positive and Receptor-Negative Human Tumor Cell Lines In Vivo and In Vitro. J. Interferon. Cytokine. Res. 1997; 17(11)681–693
  • Kangas L., Cantell K., Schellekens H. Additive and Synergistic Antitumor Effects with Toremifene and Interferons. J. Steroid Biochem. 1990; 36(3)259–262
  • Kaplan E.L., Meier P. Nonparametric Estimation from Incomplete Observations. J. Am. Statist. Assoc. 1958; 53: 457–481
  • Hamm J.T., Tormey D.C., Kohler P.C., , et al. Phase 1 Study of Toremifene in Patients with Advanced Cancer. J. Clin. Oncol. 1991; 9: 2036–2041
  • Porzolt F., Otto A.M., Trauschel B., , et al. Rationale for Combining Tamoxifen and Interferon in the Treatment of Advanced Breast Cancer. J. Cancer Res. Clin. Oncol. 1989; 115: 465–469
  • Buzzi E., Brugia M., Trippa F., , et al. Natural Interferon-Beta and Tamoxifen in Hormone-Resistant Patients with Advanced Breast Cancer. Anticancer Res. 1995; 15(5B)2187–2190
  • Repetto L., Giannessi P.G., Campora E., , et al. Tamoxifen and Interferon-Beta for the Treatment of Metastatic Breast Cancer. Br. Cancer Res. Treat. 1996; 39: 235–238
  • Chang S.M., Barker F.G.I.I., Huhn S.L., , et al. High Dose Oral Tamoxifen and Subcutaneous Interferon Alpha-2a for Recurrent Glioma. J. Neurol. Oncol. 1998; 37: 169–176

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.